Professor of Cancer Immunology and Immunotherapy
University of Cambridge, UK
http://www.roychoudhurilab.org
Roychoudhuri Lab
Loading...
Great News & Views piece on the three BACH2 dosing papers recently published in @natimmunol.nature.com
Love the title.. BACH2 the future!
www.nature.com/articles/s41...
Right BACH2 at you @roychoudhurilab.bsky.social 😆
Fantastic to see research on BACH2 from former #ListerFellow Rahul Roychoudhuri and colleagues included in Nature News and Views.
Read the paper on fine-tuning BACH2 dosage to enhance antitumor T cell therapy⤵️
www.nature.com/articles/s41...
Roychoudhuri Lab
The Lister Institute of Preventive Medicine
A compelling shift toward tissue-centric immunity: lymphoid niches don’t just initiate responses—they time and constrain them. Brilliant now work from Lukas Altenberger shows that timing of initiating and terminating immune response are equally important.
www.science.org/doi/10.1126/...
The generation of effector CD8+ T cells (TEFF) requires activation of naïve CCR7+ T cells (TN) by dendritic cells (DCs) in lymphoid tissue. How TN-DC interaction duration and signal integration are co...
www.science.org
Incredible paper from Max Krummel's lab showing macrophages can sample cellular content from living cells for presentation to T cells pubmed.ncbi.nlm.nih.gov/42056510/
Great News&Views piece covering the three papers on BACH2 dosing recently published in @natimmunol.nature.com
Love the title: BACH2 the future!
www.nature.com/articles/s41...
Immunoinformatics is revolutionising our understanding of cancer immunology and immunotherapy responses. If anyone is interested in joining our lab through this fellowship, I'd be very keen to support an application - do get in touch! www.cancerresearch.org/immuno-infor...
A great piece in ACIR discussing the there papers on #BACH2 dosing for T cell therapy of cancer recently out in
@NatImmunol
bit.ly/3atHQyV
Absolutely remarkable: striking effects of infusion time-of-day on immunochemotherapy efficacy in nonsmall cell lung cancer in a randomized phase 3 trial www.nature.com/articles/s41...
Payal Yokota
Roychoudhuri Lab
Roychoudhuri Lab
We have an active search for tenure-track faculty interested in #ImmuneEngineering #ProteinEngineering #GenomeEngineering & #CancerImmunology. Join the newly formed Center for Cellular Therapies and Cancer Immunology #CCTCI. Learn more at apply.interfolio.com/173562. #facultyjobs
Roychoudhuri Lab
Roychoudhuri Lab
Roychoudhuri Lab
Roychoudhuri Lab
Jaehyuk Choi
www.nature.com
One of three back-to-back papers to show dosage of BACH2 can modulate T cell differentiation and function and how we might apply this to enhance chimeric antigen receptor T cell therapies for cancer.
Great News&Views piece covering the three papers on BACH2 dosing recently published in @natimmunol.nature.com
Love the title: BACH2 the future!
www.nature.com/articles/s41...
Roychoudhuri Lab
The CRI Immuno-Informatics Postdoctoral Fellowship Program supports young scientists at institutions who wish to receive dual training in immunology.
In this randomized phase 3 trial, patients with treatment-naive stage III–IV nonsmall cell lung cancer who received sintilimab or pembrolizumab in combination with chemotherapy early in the day (befor...
Absolutely remarkable: striking effects of infusion time-of-day on immunochemotherapy efficacy in nonsmall cell lung cancer in a randomized phase 3 trial www.nature.com/articles/s41...
www.nature.com
In this randomized phase 3 trial, patients with treatment-naive stage III–IV nonsmall cell lung cancer who received sintilimab or pembrolizumab in combination with chemotherapy early in the day (befor...
